| Meta | Content |
|---|---|
| Rating | Neutral |
| Target Price | HKD 1.50–1.80 (base-case fair range, midpoint 1.65) |
| Current Price | HKD 1.845 (close on 2026-09-02, 52-week range 1.78–3.88) |
| Margin of Safety | −19% (no margin of safety; calculated as (base-case fair value lower bound − current price) / current price) |
| Time Horizon | 12–18 months |
| Market Cap / Close Date | HKD 7.370 billion ≈ RMB 6.313 billion (total shares 3.995 billion, as of 2026-07-31) |
| Probability-Weighted Expectation | Approx. HKD 1.63 (−11.8% vs. current price) |
| Confidence | 0.55 |
Luye Pharma is in a transition period of "old engine stalling, new engine not yet ignited": the oncology segment's 2026H1 revenue fell -35.5%, and majority-owned subsidiary Bio-Pharm Solutions (Boan Biological) saw revenue drop -40.8% with a swing from profit to loss, while the central nervous system (CNS) segment grew +22.2% to become the largest segment. The apparent +24.8% growth in 2026H1 net profit attributable to shareholders was almost entirely driven by fair value gains on exchangeable preferred shares (RMB 315 million); excluding this, recurring net profit attributable was RMB 200 million, flat year-over-year. The market has already driven the share price near its 52-week low: PB of 0.405x sits at the 0th percentile of the past 10 years, a 35% discount to the only sell-side target price being maintained post-interim results (HKD 2.85). This report uses an SOTP approach — "recurring profit of RMB 400–450 million × 8–12x + net cash + Boan's attributable market value + pipeline rNPV" — to derive a base-case fair value of HKD 1.50–1.80: the current price of HKD 1.845 is about 11% above the midpoint, meaning the current price is broadly fair to slightly rich, with no margin of safety for buyers — the deep discount at 0.4x PB has substantive causes (recurring ROE of only ~2.6%, RMB 9.16 billion of borrowings due within one year, receivables/revenue rising to 51.7%). Upside repair is event-driven: LY03015 Phase III protocol to be finalized in 2026Q4, management guidance of potential global pipeline partnerships within 12 months, and Ruoxinlin (benperidol? — if approved) GAD approval expected in 2027H1; any of these materializing points to a bull case of HKD 2.30–2.50, but the current price has already priced in a substantial portion of this option value. We recommend staying on the sidelines, waiting for the price to fall back to the HKD 1.50–1.65 range or for BD/Phase III events to materialize before reassessing entry.
One-sentence conclusion: An event option rather than a current-price opportunity — the current price is ~11% above the base-case midpoint and ~12% above the probability-weighted expectation, with insufficient margin of safety; over the next 12–24 months, the risk-reward becomes allocation-worthy only if any of the following is validated: LY03015 Phase III/BD licensing, GAD approval, or stabilization of the oncology business (or if the price falls back to the base-case range).
Key evidence:
After excluding the preferred share fair value gain of RMB 315 million and adding back the convertible bond redemption loss of RMB 58 million and FX loss of RMB 66 million, this report estimates 2026H1 recurring net profit attributable at RMB 199.6 million, essentially flat versus RMB 198.9 million in the prior-year period; moreover, the 2025H1 adjusted figure included RMB 280 million of one-off technology sales, making the "true operating base" flatness even weaker. The flip side of flatness is structural deterioration: gross margin fell 67.8%→63.4% (-4.4pp), current income tax rose +140% (effective tax rate 21.9%→26.1%), offset entirely by selling expenses -21.5% (expense ratio 32.0%→26.7%) — whether cost compression is structural is unclear; the company attributes it only to "reductions in promotional, staff and conference expenses," with no evidence of restructuring. Marginal improvement: 2026H1 product sales turned positive at +1.5% (RMB 2,880 million vs. RMB 2,837 million), though growth is weak. The stock fell -9.39% in a single day on 8/31, the day after interim results — the market has already spoken.
Key evidence:
After caliber breakdown: the oncology segment's -35.5% includes base effects (2025H1 included RMB 280 million of one-off "product technology sales"); pure product sales declined about -21% YoY and about -16% sequentially. On the -25% to -30% sequential slope, this report estimates FY2026 oncology segment revenue at approximately RMB 1.55 billion (FY2025: RMB 2.297 billion, including ~RMB 400 million of technology sales), a single-year contraction of ~RMB 750 million, of which ~RMB 400 million is one-off base clearance. Lipusu (paclitaxel liposome), the flagship product, faces dual price and clinical pressure from CSPC/Hengrui's albumin-bound paclitaxel (already in centralized procurement). At Boan's level, bevacizumab (11 domestic players) and denosumab have been listed in the biologics alliance procurement catalog; if implemented in 2026H2–2027 and assuming common biosimilar procurement price cuts of 40–70%, Boan's FY2025 revenue of ~RMB 770 million could fall to RMB 400–550 million, with goodwill (Group: RMB 1.034 billion) and intangible asset impairment risks. The hedges are real too: two US denosumab BLAs have been accepted (targeting Amgen's Prolia/Xgeva combined market of ~USD 5–6 billion), and US rights to BA5101 (dulaglutide) were licensed out in June 2026 (upfront + milestones + royalties), giving Boan a loss-reduction path in 2027 — the certainty of "drag continuing" should not be overestimated.
Key evidence:
Cash-like assets of RMB 13.33 billion − interest-bearing debt of RMB 11.99 billion = net cash of +RMB 1.34 billion (2026-06-30), but after excluding pledged deposits of RMB 2.57 billion, this turns into net debt of approximately -RMB 1.22 billion — the "net cash floor" is highly dependent on restricted assets, which is the substance of the market discount. Adjusted EBITDA (excluding the non-cash preferred share fair value gain) of ~RMB 1.99 billion covers annualized interest of ~RMB 610 million about 3.3x (the apparent 4.1x overstates the buffer by ~25%); unrestricted cash of RMB 10.76 billion covers within-one-year maturities (including current CB) of RMB 9.70 billion about 1.11x. In the base case (normal renewal of facilities), the company can roll over without default risk — the market's real-money subscription of the USD 180 million 5.25% five-year CB in June 2026 is the most direct market bid on credit risk; however, the company has no FX/interest-rate hedging and carries HIBOR floating-rate loans; in a stress scenario (discount facility contraction + receivables deterioration), we look to P/B of 0.30x ≈ HKD 1.40. The new CB conversion price of HKD 2.71 is +47% above the current price; total potential dilution is ~15.7% (new CB 521 million shares + preferred shares 77 million shares + legacy bond remainder), so a rally into the HKD 2.4–2.7 range will face overhead supply and dilution-driven selling pressure.
Key evidence:
CNS growth is driven by Ruoxinlin (volume ramp post-successful November 2024 NRDL negotiation) + Rykindo long-acting injectable + the overseas platform (Erzofri record share of US institutional customers), the only confirmed growth engine in the financials. LY03015 (the world's first dual-target VMAT2 inhibitor + Sigma-1R agonist) addresses a white space in China's TD market (no approved VMAT2 drug domestically; Ingrezza FY2025 sales of USD 2.51 billion, FY2026 guidance of USD 2.83–2.88 billion), with dual China-US filings. But three points must be acknowledged: ① The Phase II 20mg group sample was ~30 subjects; "nearly double historical data" is a cross-trial comparison, not head-to-head, and the confidence interval around the 76.5% response rate is wide; ② US bridging trials show safety divergence — TEAE 33.3% in white subjects vs. 83.3% in Chinese subjects; the company adopted a "simplified dosing" regimen in the US accordingly, and if this raises Phase III AE/discontinuation rates it would directly threaten the registration path; ③ Management's BD language is conditional ("some global collaboration opportunities may be reached"), with no company guidance on upfront size — this report assumes scenarios of USD 30–150 million (USD 100 million ≈ 10.6% of market cap), which is an estimate, not a fact. The Phase III protocol landing in 2026Q4 and the initiation of US efficacy trials would be the first verifiable node in upgrading the "Phase II story" to a "registration asset."
Key evidence:
Three-layer decomposition: current price = EPV zero-growth HKD 1.17 (63.4%) + growth option premium HKD 0.68 (36.6%), while the quantifiable rNPV of the three key pipeline assets totals only HKD 0.32/share — the current price pays ~2x their quantifiable value for the options; the difference must be explained by the US CNS platform (Erzofri/Rykindo), LY03015's Huntington's disease indication, and BD premium (this report estimates HKD 0.1–0.2). PB of 0.405x vs. recurring ROE of ~2.6% (theoretical EPV PB ≈ 0.26x) — book assets fail to earn the cost of capital, so the low PB is mostly "deserved" rather than "wrongly punished." Three scenarios: bear HKD 0.75–0.90 (25%) / base HKD 1.50–1.80 (50%) / bull HKD 2.30–2.50 (25%); probability-weighted expectation ~HKD 1.63 (-11.8%). The systematic divergence from sell-side prices is a caliber dispute: HKD 2.85–2.94 implies "reported earnings × own historical median PE of 16.8x," without excluding non-cash fair value gains; moreover, the current price stands at a 31% discount to the lowest published TP — the trading market likewise is not pricing at sell-side TPs. Conclusion: weaker fundamentals (cause of the price) coexist with fair valuation (price level) — the odds of buying at the current price are asymmetric to the downside; recovery depends on events.
| Metric (RMB 100 million) | FY2023 | FY2024 | FY2025 | 2026H1 (latest) |
|---|---|---|---|---|
| Operating revenue | 61.43 | 60.61 | 63.08 | 30.02 |
| Revenue YoY | — | -1.3% | +4.1% | -5.6% |
| Net profit attributable to parent | 5.33 | 4.72 | 6.19 | 3.91 |
| Attributable net profit YoY | — | -11.4% | +31.1% | +24.8% |
| Recurring attributable profit (this report's estimate)* | 3.97 | 5.62 | 3.57 | 2.00 |
| Gross margin | 68.4% | 66.7% | 66.0% | 63.4% |
| Attributable net margin | 8.7% | 7.8% | 9.8% | 13.0% |
| R&D expenses | 5.86 | 4.99 | 4.14 | 2.57 |
| Operating cash flow** | 15.95 | 1.68 | 17.83 | Not disclosed |
| Free cash flow** | 9.62 | -4.26 | 12.72 | Not disclosed |
| Cash and cash-like assets | — | — | 88.76 (2025-12-31) | 133.34 (2026-06-30) |
| Interest-bearing debt (incl. convertible bonds) | 84.24 | 103.21 | 94.17 | 119.87 |
| Gearing ratio (borrowings/equity, company caliber) | — | — | 45.5% | 58.6% |
| Net cash (total caliber) | — | — | -5.42 | +13.47 |
*Recurring caliber is this report's estimate (excluding preferred share/CB fair value changes, CB redemption losses, FX gains/losses, gains on asset disposals and other one-off items; pre-tax caliber); the company does not disclose Non-GAAP/adjusted profit. **Operating cash flow is anchored to external database values (results announcements exclude cash flow statements), pending full annual report verification.
Reasons for metric changes (YoY ≥ ±20% items with management explanations): ①FY2025 attributable profit +31.1%: company attributes to "launch of high-margin new products and expense control," but includes preferred share fair value gain of RMB 157 million + FX gain of RMB 105 million (combined 42% of the total); ②2026H1 attributable profit +24.8%: preferred share fair value gain of RMB 315 million, CB redemption loss of -RMB 58 million, FX loss of -RMB 66 million; net one-off impact +RMB 191 million (49%); ③Oncology segment 2026H1 -35.5%: "reduced sales of certain key products and product technologies" (2025H1 included RMB 280 million of one-off technology sales); ④Selling and distribution expenses 2026H1 -21.5%: "reductions in promotional expenses, staff costs and conference expenses"; ⑤Other expenses 2026H1 +86.8%: "increased R&D costs, loss on redemption of convertible bonds and FX losses" (R&D +32.8%); ⑥Cardiovascular segment FY2025 -30.6%: "reduced sales of certain cardiovascular system products" (vague attribution, products not named); ⑦FY2025 finance costs +22.2%: "increased interest on bank borrowings and convertible bonds"; ⑧Government subsidies fell sharply from RMB 162 million to RMB 39 million in FY2025 (-76%), not separately explained by the company; ⑨Cash 2026H1 +82.9% vs. beginning of year: June issuance of USD 180 million new CB + increased borrowings.
Revenue RMB 3.002 billion (-5.6%): CNS RMB 1.060 billion (+22.2%, share up to 35.3%) became the largest segment for the first time; Oncology RMB 836 million (-35.5%, share 27.8%); product sales basis +1.5% (RMB 2.880 billion), the total revenue decline was mainly because the RMB 280 million one-off product technology sales from the prior-year period did not recur. Net profit attributable to shareholders RMB 391 million (+24.8%): poor quality of growth — excluding one-off items such as fair value gains on preference shares, recurring net profit was RMB 200 million, flat YoY (the company's own measure "net profit before preference shares and CB impact" was RMB 181 million, -61% YoY, due to the high base including technology sales in the prior year); gross margin 63.4% (-4.4pp, the company attributed it to "increased cost of sales," vaguer than the annual report's "higher share of lower-margin products"); minority interests swung from +RMB 44 million to -RMB 10 million (Boan's losses borne by minority shareholders, boosting the attributable share, unexplained by the company). Sharp balance sheet changes: cash RMB 8.216 billion (+82.9% vs beginning of year), interest-bearing debt RMB 11.987 billion (+27.2%), gearing ratio 45.5%→58.6% — driven by the June CB exchange (refinancing) plus increased borrowings; net cash swung from -RMB 540 million to +RMB 1.35 billion. Judgment: this interim report shows "profit growth without revenue growth," with no recurring basis for profit growth; the market's -9.39% repricing the next day was rational. With no management quantitative guidance to benchmark and sell-side consensus unavailable (only 1 broker covering), we make no market conclusion on "beat/miss."
Business model: Asset-heavy specialty pharma — microsphere/liposome/transdermal complex formulation platforms + 8 production bases + direct hospital sales and a network of ~1,770 distributors (covering ~22,600 hospitals); 90%+ of revenue from product sales (recurring), supplemented by project-based, volatile out-licensing (FY2025 RMB 229 million) and "product technology sales" (FY2025 RMB 400 million); CNS specialist narrow channels and complex formulation capabilities form the main moat, but bargaining power downstream with payers/hospitals is weak (gross margin down four years in a row).
Cash content of earnings: OCF/attributable net profit FY2023–FY2025 was 3.0 → 0.36 → 2.88 (external database anchored values), extremely volatile and FY2024 profit had almost no cash backing; FCF/net profit 1.81 → -0.90 → 2.06. Receivables are the biggest quality signal: trade receivables +38% over three years (RMB 2,355→3,259 million) while revenue grew only +2.7%; receivables/revenue rose yearly from 38.3%→45.9%→51.7%; the 6–12 month aging balance quadrupled from RMB 215 million to 662 million, and the company only stated "no significant credit concentration risk." Recurring earnings test: of FY2025 reported attributable net profit of RMB 619 million, ~RMB 261 million (42%) came from one-off items (preference share fair value + FX); core recurring profit was RMB 357 million, -36% YoY (FY2025 recurring was RMB 562 million including asset disposal gains; on a like-for-like basis the true operating trend is "step down then stabilize") — the headline +31.1% was entirely dressed up by non-cash items.
Return on capital: ROIC ~2.5% (NOPAT RMB 706 million ÷ invested capital RMB 27.78 billion, FY2025), far below a typical pharma WACC (10%) — the RMB 6.78 billion intangibles + RMB 1.075 billion goodwill from historical M&A (together 23.9% of total assets) are a black hole for returns; long-term ROIC < 8% is a "pseudo-growth" warning zone. Maintenance CapEx: CapEx/depreciation 0.90 → 0.75 → 0.61, below 1 — expansion converging, not a capital black hole. Red flag list: ① 2026H1 attributable profit growth was 49% from one-off items; ② FY2025 product sales actually -0.5% (total revenue +4.1% relied entirely on licensing/technology sales); ③ receivables/revenue at 51.7% with long-aging balances doubling year after year; ④ RMB 1.029 billion of trade receivables pledged as collateral for borrowings (zero at end-2025); ⑤ zero dividends for many consecutive years.
Credibility of words vs actions: pragmatic (clinical/regulatory milestones 5/5 delivered, profit guidance vague). ① Committed to China approvals of liraglutide and aflibercept in 2025 → actually approved August/November 2025 (delivered); ② committed to submitting two denosumab BLAs in the UK by end-2025 → accepted November 2025, submitted to FDA in May 2026 and accepted in July (delivered); ③ FY2025 annual report committed to LY03015 China Phase II readout mid-2026 → met primary endpoint in June 2026 (delivered); ④ committed to "global partnership within 12 months" → US rights of BA5101 out-licensed in June 2026 (delivered); ⑤ "R&D spending controlled within a certain amount" → FY2025 R&D -17% (delivered); "net margin restored to industry level" → 7.8%→9.8%, directionally delivered but still low in absolute terms (partially delivered). No quantitative profit guidance was ever given; there is a disclosure strategy of "offsetting vague profit messaging with milestone delivery."
Shareholder friendliness: leaning unfriendly. FY2023–FY2025 and all interim reports: zero dividends, zero buybacks (the 2026 AGM renewed the 10% buyback mandate but it has never been executed); share count 2023–2026 +7.1% (weighted basis, 3,728→3,995 million shares); two convertible bond rounds totaling USD 330 million issued in 2024, plus another USD 180 million CB in June 2026 (potential dilution 13%); Nanjing Luye received external capital injection of RMB 285 million in January 2026 (at the minority shareholder level). Risk signals: ① Chairman and CEO are the same person (Liu Dianbo, ~33.5% shareholding), a deviation from CG Code provision C.2.1 acknowledged by the company; ② Nanjing Luye's strategic investor entry carries a put/bet-on agreement — aggregate net profit of no less than RMB 1.086 billion for 2025–2027 and no less than RMB 857 million for 2028–2029; upon trigger, investors may exit at principal + 8.5% simple interest (in December 2025 a fund already exited by transferring 25% equity for RMB 1.086 billion), yet the interim report's "contingent liabilities" section only says "no material contingent liabilities" — tension between the disclosure and the media-verified bet-on terms; ③ controlling shareholder provided personal guarantee for a RMB 495 million loan, and shares in subsidiaries were pledged. Liu Dianbo increased his stake twice in December 2024–January 2025 (average price HKD 2.23; current price ~17% below that).
FY2025 segment structure (2026H1 in parentheses):
| Segment | Revenue (RMB 100M) | Share | Segment margin* | YoY | One-line business logic |
|---|---|---|---|---|---|
| Oncology | 22.97 | 36.4% | 46.5% | +10.2% (26H1 -35.5%) | High-margin liposome complex formulations, but flagship squeezed by albumin paclitaxel; base includes one-off technology sales |
| CNS | 20.28 | 32.1% | 42.8% | +25.7% (26H1 +22.2%) | Growth engine: Ruoxinlin volume under NDL insurance + Ruixintuo long-acting injectable + overseas platform; became largest segment in 26H1 |
| Cardiovascular | 11.52 | 18.3% | 21.8% | -30.6% | Legacy products like Xuezhikang, high volume but thin margin and fastest decline |
| GI & Metabolism | 3.47 | 5.5% | 37.2% | -10.3% | Legacy products like Beixi + Boyouping (GLP-1, approved Aug 2025) contributing increments from 2026 |
| Others (Boan ophthalmology/orthopedics, etc.) | 4.80 | 7.6% | 4.3% | +53.2% | Boan biosimilars ramping in EU but very low margin (includes EU revenue of RMB 539 million) |
*Segment result / segment revenue (approximates segment gross margin). The profit mainstay is Oncology: FY2025 Oncology segment result RMB 1.068 billion, 45.7% of total segment results — the largest revenue segment is also the profit mainstay, yet it is exactly the segment collapsing hardest in 2026; this is the structural root of the current earnings downturn. CNS segment result RMB 867 million (37.1%) is the second engine. Gross margin structure gap between 46.5% (Oncology) and 21.8% (Cardiovascular) is 24.7pp: Oncology relies on liposome complex formulation barriers and specialty channel premiums; Cardiovascular is fully competitive, aged generics with no bargaining power over payers — under the same consolidated statements these are two entirely different businesses. In 2026H1 the structure has flipped: CNS at 35.3% > Oncology at 27.8%; whether the baton pass of the profit mainstay completes depends on the race between Oncology's bottoming and CNS's growth rate.
Accounting red flags: ① Receivables growth persistently and significantly above revenue (medium severity): receivables +38% over three years vs revenue +2.7%; 6–12 month aging RMB 215→414→662 million, doubling yearly; the company only states no concentration risk; ② One-off fair value gains underpin profit growth (medium): preference share/CB fair value changes exceeded 40% of attributable profit for two consecutive periods; "other income and gains" +130.8% in 2026H1 mainly due to preference share fair value; ③ Inconsistent gross margin attribution (low): FY2025 cited "rising share of lower-margin product sales," 2026H1 changed to "increased cost of sales"; the explanation for the four-year decline (68.4%→63.4%) suddenly became vague; ④ Government subsidies fell 76% with no separate explanation (low).
Cross-period consistency: ① OCF/attributable net profit 3.0→0.36→2.88, extremely volatile — unexplained by the company (results announcements omit cash flow statements); ② receivables/revenue 38.3%→45.9%→51.7%, rising yearly — unexplained by the company; ③ R&D expense ratio 9.5%→8.2%→6.6%→8.6% (26H1), cut then re-expanded — consistent with management statements ("R&D controlled within a certain amount," then re-investment in 2026); ④ minority interests swung sharply from +0.65→+1.73→+0.87→-0.10 (RMB 100M), directly amplifying attributable profit elasticity — unexplained by the company (Boan-level P&L allocation undisclosed); ⑤ gross margin declined four periods in a row with drifting attribution — inconsistent. Overall judgment: no evidence of fabrication found, but the combination of "declining earnings quality + key items unexplained" requires a sufficient discount to headline earnings.
Current market data (closing price 2026-09-02): share price HKD 1.845, market cap HKD 7.370 billion (RMB 6.313 billion); PE(TTM) reported basis 9.19x (1/3/5/10-year percentile 0%/2%/1%/5% — TTM earnings include RMB 315 million of non-cash gains; percentiles are reference only); recurring PE(TTM) 17.63x, static FY2025 reported 10.2x, FY2026E recurring forward PE ~14.9x; PB 0.405x (10-year 0% percentile); PS(TTM) 1.03x; EV/Sales 0.81x. FX rate: 1 RMB = 1.167364 HKD.
Peer benchmarking (the company itself shown on a like-for-like basis):
| Company | Mkt cap (HKD 100M) | 2025 revenue (RMB 100M) | Revenue growth | Gross margin | PE |
|---|---|---|---|---|---|
| Luye Pharma | 73.7 | 63.1 | +4.1% (26H1 -5.6%) | 63.4% (26H1) | 9.2x reported / 17.6x recurring |
| CSPC Pharmaceutical | ~1,115 | 260.1 | -10.4% | 65.6% | 29.3x |
| Hansoh Pharmaceutical | ~2,205 | 150.3 | +23% | 91.1% | ~29x |
| Sino Biopharmaceutical | ~1,000 | 318.3 | +10.3% | 82.1% | — |
| Boan Biotechnology (Holdings) | 21.8 | 26H1 2.33 | -40.8% | — | loss-making |
Market-implied expectations: back-solving from the current price — market cap RMB 6.313 billion − net cash RMB 1.34 billion − Boan's attributable market value of HKD 1.26 billion (57.94%×2.18 billion) ≈ RMB 3.9 billion for the existing business + pipeline, i.e., the market pays only ~8–12x recurring earnings for the existing drug business (peers at 29x), 0–0.3 HKD/share in total for the three key pipeline assets, and only 40 cents on the dollar for book net assets (HKD 4.55/share). The current price requires the market to believe: Oncology keeps collapsing + recurring profit grows low single digits + pipeline options are nearly free; yet the reality is recurring profit has stabilized (+0.4%), CNS is growing double digits, and LY03015 met its Phase II endpoint — the market is not entirely wrong (Boan losses, RMB 9.16 billion of short-term debt, deteriorating receivables are all real); the divergence is fundamentally about pricing the credibility of book assets and BD delivery.
Three-tier value (EPV): Asset value (book floor) HKD 4.55/share — of which ~60% is intangibles/goodwill with impairment risk under centralized procurement; hard assets are only net cash 0.39 + Boan 0.32 = HKD 0.71/share; EPV at zero growth HKD 1.17/share (10x recurring earnings incl. interest income, range 0.93–1.40; ex-interest decomposition ~0.90 — the difference lies in whether interest income on cash-like items is separated; both measures avoid double counting with net cash); growth option premium HKD 0.68/share, 36.6% of current price (EPV is 63.4%). The growth option share is not small — the current price is not "the market pays only for zero growth" but has already paid roughly 2x the quantifiable rNPV for the pipeline; whether BD delivers determines whether this option premium pays off. Note: consolidated net cash includes the portion attributable to Boan's minority shareholders, with an overlap of ~HKD 0.05–0.06/share against the Boan market value layer, already covered by the EPV range width.
Three scenarios and odds (rNPV/SOTP breakdown in Chapter XI):
| Scenario | Probability | Fair range (HKD) | vs current price | Key swing factors |
|---|---|---|---|---|
| Bear | 25% | 0.75–0.90 (mid 0.83) | -60%~-51% | Oncology + Boan keep deteriorating and short-term refinancing blocked; adjusted interest coverage of 3.3x breached |
| Base | 50% | 1.50–1.80 (mid 1.65) | -19%~-3% | Oncology decline narrows + CNS hedge + recurring attributable profit RMB 400–450 million; lower bound = ex-interest SOTP sum of 1.53, upper bound = incl.-interest EPV of 1.80 |
| Bull | 25% | 2.30–2.50 (mid 2.40) | +24%~+35% | LY03015 BD deal lands (upfront USD 30–150 million scenario) + GAD approval + US CNS delivery |
Probability-weighted expectation ~HKD 1.63 (-11.8%) — odds skew to the downside; the right tail (+24%~+35%) and left tail (-51%~-60%) net to ~-12% after probability weighting. Base-case anchoring rationale (independent of current price): the lower band 8–12x of the median 16.8x of the stock's own 10-year PE distribution (7.4–33.9x) × recurring earnings + SOTP segment sum; ~60% discount to peers' 29x, justified by negative revenue growth (peers +10~23%), gross margin 63% vs 82–91%, recurring ROE 2.6% — none of the comparables is truly like-for-like; mechanically applying 29x would overvalue. Bear-case anchor: the most pessimistic published price target is investing.com's low TP of 2.68/Futu 2.85 (only 1 analyst, pricing on reported earnings × historical median PE); this bear case is significantly below that anchor — because those TPs do not strip out non-cash fair value gains and do not price the refinancing-blocked tail; the current price is at a 31% discount to the lowest TP, and the market is likewise not bidding at sell-side TPs. Comparison with both market ends: this base range (1.50–1.80) is below the most pessimistic published TP (2.68) — the difference mainly comes from the earnings basis (recurring vs reported) and holding/liquidity discounts (SOTP after a 15–20% discount gives 1.22–1.53); if sell-side coverage resumes or a BD deal shifts the market to a recurring + SOTP basis, the anchor would move up — this is the main calibration risk to this judgment.
Own earnings forecast (reconciliation anchor): FY2026 revenue RMB 6.00–6.15 billion (-2.5%~-5%); reported attributable profit RMB 550–650 million / recurring RMB 400–450 million (H2 centralized procurement execution + rising tax burden; risk of an overly optimistic annualized base is already factored into the range); FY2027 recurring attributable profit RMB 500–650 million (GAD approval ramp, Oncology base cleared, Boan losses narrowing). Management gives no quantitative guidance (qualitatively: "new product ramp + mix optimization; possible global partnership within 12 months"); sell-side consensus unavailable (1 broker covering).
Conclusion: Fair, leaning slightly stretched — assess quality and price separately: quality is weak (ROIC 2.5%, deteriorating receivables, zero dividends, Oncology collapse), but price largely reflects the weakness (0% percentile PB + 37% option premium). Target price HKD 1.50–1.80 (base-case fair value); current price HKD 1.845, margin of safety -19% — not a buy; wait on the sidelines until catalysts (BD/Phase III/GAD) or price (pullback to 1.50–1.65) materialize.
Market size: China's innovative drug market has no single official figure in billions of RMB; triangulation across three anchors: ① Supply side — combined revenue of Chinese innovative drug listed companies exceeded RMB 100 billion in 2025 (Wind/NBD scope), with the HK 18A segment generating over RMB 96.5 billion; ② Approval side — NMPA approved 76 innovative drugs in 2025, a record high (NMPA, via Cailian Press); ③ Deal side — total license-out deal value of USD 135.655 billion in 2025, up 161% YoY, across 157 deals with ~USD 7 billion in upfront payments (PharmCube NextPharma); China for the first time accounted for ~49% of global out-licensing value; USD 53.3 billion more was signed in Jan–Feb 2026. The industry's 5-year CAGR is ~20% (Zhiyan Consulting scope, third-hand source, unverified; no official association figure obtained) — headline figures use supply-side/approval-side official and first-tier institution data; aggregator sites are used only for cross-reference. Two subsegments matter more for Luye: ① Tardive dyskinesia (TD) — the global drug market was ~USD 3.6 billion in 2026, projected to reach USD 7.22 billion by 2034 (CAGR 9.1%, Fortune Business Insights, third-hand, unverified; the company cites Cortellis at ~USD 5 billion/year); competitor Ingrezza (valbenazine) posted FY2025 net sales of USD 2.51 billion (+9%, Neurocrine official IR), with FY2026 guidance raised to USD 2.83–2.88 billion; Austedo (deutetrabenazine) was ~USD 2.1–2.2 billion in FY2025 — the TD drug market is a US duopoly still in early penetration (TD prevalence among antipsychotic-treated patients is ~25.3%; ~33.7% among Chinese long-term schizophrenia medication users, a potential pool of 1.5–2.5 million people; China has no approved VMAT2 drug and penetration is near zero); ② HPV therapeutic vaccines — the global front-runner is Inovio's VGX-3100 (DNA vaccine; positive Phase III topline in China in May 2026; media assess a ~5-year lead over RNA-based competitors), while BioNTech and other mRNA routes are at early Phase I/II; Luye's LY01620 is in China's first tier but trails by one Phase III step.
Value chain and value distribution: Upstream (APIs/CXO/complex formulation equipment) is well supplied, giving pharma strong bargaining power — Luye holds its own Yantai and US capacity and self-developed microsphere technology end-to-end, with low upstream dependence; the midstream (integrated R&D–registration–manufacturing–academic promotion) captures the vast majority of industry gross margin; downstream payers are dominated by the National Reimbursement Drug List (tertiary hospitals + DRG/dual-channel determine volume ramp), with commercial insurance contributing incremental growth from 2025. Luye sits in the integrated midstream — strong vs. upstream, weak vs. downstream — the oncology line faces double price compression from same-class novel drugs and VBP (Lipusu being displaced by albumin-bound paclitaxel; Baion's bevacizumab/denosumab candidates for VBP inclusion); license-out deals and the commercial insurance list are the only two repricing channels; its CNS psychiatric specialty narrow channel is a unique channel moat.
Supply, demand, and competitive structure: On the demand side, both "volume" (aging population; Ruoxinlin's NRDL-driven ramp with Q1 2025 revenue +200%; rising TD awareness) and "price" (opening of the innovative drug commercial insurance list; BD monetization ahead of overseas launches) are expanding; on the supply side, structural divergence — truly differentiated assets (FIC/BIC) are scarce and fought over by multinationals (Sanofi-Pfizer's record USD 1.25 billion upfront), while me-too drugs and biosimilars face overcapacity and normalized price wars (PD-1; 11 bevacizumab biosimilars in the same arena). Industry concentration is low (no authoritative CR3/CR5 obtained), but structurally consolidating toward leaders with high innovative drug revenue share: Sino Pharma at 47.8%, Hansoh at 82.2% (rising to 85.4% in H1 2026), Luye at ~50–60% (new-product driven). Entry barriers are high (10-year cycles, ~USD 1 billion per-drug investment, specialty channels and complex formulation know-how that are nearly impossible to replicate), but the generic-to-innovative transition zone is the most fiercely contested — Luye's oncology line at -35.5% in H1 2026 is a direct manifestation of this rivalry.
Cycles and regulation: The industry is in "mid-to-late growth + cyclical upswing": BD out-licensing at record highs and the profitability inflection point at leading players confirmed (industry revenue topping RMB 100 billion in 2025; Hansoh/Sino Pharma with double-digit profit growth); but internally stratified — generics/biosimilars are in a VBP-driven, downward clearing phase, with "innovative up, generic down" dual cycles overlapping. Four regulatory themes: ① 2024 "full-chain support for innovative drugs" → 30 June 2025 NHSA/NHC "Measures to Support High-Quality Development of Innovative Drugs" (16 measures); ② 2025 NRDL added 114 drugs (including 50 Class 1 innovative drugs) and removed 29, effective 1 January 2026; ③ first batch of 19 drugs on the commercial insurance innovative drug list (including 5 CAR-Ts), cementing a dual-track payment system; ④ VBP expanding from generics to biosimilars (Baion's bevacizumab/denosumab included). The impact on Luye is divergent: the CNS innovative line (Ruoxinlin/Ruixintuo/TD pipeline) benefits from payment expansion and VBP exemption, while the oncology liposomal line and Baion's biosimilar line are directly harmed. Leading indicators: annual NMPA approvals, license-out deal values and upfronts, and NRDL/commercial insurance list inclusions (2026 adjustment to be released by end of November).
Company positioning: Leader in China's CNS space + a mid-sized specialty pharma under pressure in oncology/biosimilars (a chaser). CNS is the largest segment at +22.2%, with three parallel thrusts — long-acting injectables (Ruixintuo/Seroquel family), oral (Ruoxinlin), and overseas (Erzofri hitting record US institutional customer share); the microsphere/liposome sustained-release platforms and psychiatric specialty channels form a hard-to-replicate moat; LY03015 is positioned for China's first TD launch (First-in-class dual target) with dual China-US filings. Share trend: rising within CNS, declining within oncology. Market cap of HK$7.37 billion vs. peers (CSPC 111.5 / Hansoh 220.5 / Sino Pharma 100.0 billion HKD) — Luye trades at 1/15–1/30 of peers' market cap and 0.405x P/B; the market's pricing of its "CNS niche + pipeline optionality" lags the industry's cyclical upswing; re-rating depends on TD/mRNA pipeline delivery and debt resolution.
Pipeline overview (core assets; ownership/licensing noted):
| Asset | Indication | Stage (as of Aug 2026) | Key data/milestones |
|---|---|---|---|
| LY03015 (owned, Class 1 chemical) | Tardive dyskinesia / Huntington's chorea | China Phase II completed (primary endpoint met Jun 2026); US PK bridging completed; Phase III protocol to be finalized in Q4 2026 | 20mg arm AIMS response rate 76.5% (p<0.01, n≈30); TEAE in Caucasian/Chinese subjects 33.3%/83.3% |
| Ruoxinlin (owned, marketed) | Depression → generalized anxiety disorder (GAD) | GAD NDA accepted Jan 2026; approval expected H1 2027 | GAD Phase III enrollment completed Aug 2025; depression indication successfully negotiated into NRDL Nov 2024 |
| LY03017 / LY03020 / LY03021 (owned) | Parkinson's disease psychosis / schizophrenia (TAAR1×5-HT2CR dual target) / depression | Phase II initiated (first patient Apr 2026) / Phase II / Phase I | World's first TAAR1×5-HT2CR; US INDs all approved |
| LY01620 (owned, Class 1 biologic) | HPV16+ cervical HSIL (therapeutic mRNA) | China Phase II about to begin (announced 20 Aug 2026) | Preclinical viral clearance near 90%; trails Inovio by one Phase III step |
| BA6101/BA1102 denosumab (Baion) | Osteoporosis / giant cell tumor of bone + bone metastases | US BLA accepted Jul 2026, approval expected H1 2027; UK MAA under review | Benchmarked against Amgen's Prolia/Xgeva, a combined USD 5–6 billion market |
| BA5101 dulaglutide (Baion) | Type 2 diabetes | Approved in China (Aug 2025) and in NRDL; US rights out-licensed Jun 2026 | World's first Trulicity biosimilar; upfront + milestones + royalties |
| BA1104 nivolumab biosimilar (Baion) | NSCLC etc. | Phase III enrollment completed; BLA to be filed by end of 2026 | First Opdivo biosimilar to enter Phase III; FDA agreed to an abbreviated pathway |
| BA1301/BA1302 ADCs (Baion) | CLDN18.2+/CD228+ solid tumors | Phase I (BA1301 data at ASCO 2026; BA1302 Ia completed) | Gastric cancer ORR 29% / biliary tract cancer 30%; PRs across multiple tumor types |
Core asset rNPV (built in-house for this report; all assumptions listed): ① LY03015: peak sales of RMB 1.2 billion (potential Chinese patients 1.5–2.5 million × ~300,000 treated per year × ~RMB 4,000 annual treatment cost, benchmarked to the US duopoly market of USD 4.7 billion), net margin 27.5%, exit at 8x PE in 2033, 11% discount rate, POS 50% (Phase II met endpoint but Phase III not yet started) → rNPV ≈ HK$740 million (HK$0.19/share); ② Ruoxinlin GAD increment: incremental peak RMB 600 million, POS 50% (approval probability 85% × penetration realization 60%) → ≈ HK$420 million (HK$0.10/share); ③ LY01620: peak RMB 900 million, POS 12%, 15% discount rate → ≈ HK$110 million (HK$0.03/share). ΣrNPV ≈ HK$1.27 billion ≈ HK$0.32/share. Sensitivity: if LY03015 POS rises to 65% or peak sales are revised up to RMB 1.8 billion, rNPV rises to ~HK$0.28–0.30/share — even doubling would explain only 60% of the current option premium embedded in the share price.
SOTP vs. current price: ΣrNPV HK$1.27 billion + net cash HK$1.56 billion + attributable Baion market value HK$1.26 billion (57.94% × HK$2.18 billion) + EPV of existing business ex-interest HK$2.01 billion = HK$6.10 billion (HK$1.53/share, no discount); including interest (interest income on net cash folded into EPV), upper bound HK$7.20 billion (HK$1.80/share); applying a 15–20% holding/liquidity discount (small cap, multi-layer structure, Baion consolidated) → HK$1.22–1.53/share. The current price of 1.845 is above the top of the no-discount range — the SOTP framework does not support an "undervalued" conclusion; the gap between the current price and SOTP (~HK$0.3–0.6) must be explained by the US CNS platform, the early LY03017/20/21 pipeline, and a BD premium.
Clinical milestone calendar (12–24 months): Q4 2026 LY03015 Phase III protocol finalized + China/US launches (high-risk event: protocol delay or safety design disputes); Nov 2026 NRDL/commercial insurance list results; end of 2026 BA1104 BLA submission; Mar 2027 2026 annual report (dual validation of oncology/short-term debt); H1 2027 Ruoxinlin GAD approval + two denosumab US approvals (if achieved, Baion loss reduction + milestone cash); H2 2027 BD licensing window (management guidance: within 12 months).
Cash runway: Cash-like assets of RMB 13.33 billion (including restricted RMB 2.57 billion) vs. RMB 9.70 billion due within one year — coverage of 1.11x (unrestricted basis) and 1.45x (total basis); annual operating cash inflow on the order of RMB 400–600 million + credit line renewals + potential BD upfronts — refinancing disruption is a bear-case trigger, not the base case; no equity financing plans disclosed, but full CB conversion would dilute ~13%.
Mechanism-level competition: TD — LY03015 is the world's first VMAT2+Sigma-1R dual-target drug; direct competitors valbenazine/deutetrabenazine are both unapproved in China, making China's first-mover advantage real; in the US market, it faces Ingrezza's first-mover position and a potential generics-driven price reset after Austedo's patent expiry around 2028. HPV mRNA — Inovio leads by one step (positive China Phase III), BioNTech is early-stage; commercialization for all is a post-2030 story.
Overall rating: Neutral, confidence 0.55, time horizon 12–18 months. Luye Pharma's "deep discount" reflects a combination of nominal metrics (PB at 0th percentile) and actual quality (ROIC 2.5%, deteriorating receivables, oncology collapse, zero dividends): the market is not mispricing — it simply refuses to pay for the pipeline before evidence arrives. Base fair value is HK$1.50–1.80; the current price of HK$1.845 is above the top of the range with no margin of safety; three scenarios at 0.75–0.90/1.50–1.80/2.30–2.50 (25%/50%/25%), probability-weighted expectation HK$1.63 (-11.8%) — odds skew downward but the right tail is fat, suitable for event-driven tracking rather than left-side position building.
Strategy: ① Price path — a pullback to the HK$1.50–1.65 range (base-case center band) turns risk/reward positive; positions can be assessed in tranches; a break below HK$1.40 (P/B 0.30x) implies bear-case pricing and calls for re-examining refinancing assumptions rather than adding; ② Event path — a LY03015 BD licensing announcement (upfront ≥ USD 100 million) or Phase III protocol landing on schedule would shift the view toward the bull case of 2.30–2.50; ③ Sell/avoid discipline — a rebound into the HK$2.40–2.71 range enters the CB break-even and dilution selling pressure zone; under a neutral view, positions should be exited above 2.40.
Key risk disclosures (written summary): RMB 9.16 billion of short-term debt relies on rolling renewal via discounted bills (40.6%), with pledged deposits up RMB 1.2 billion in six months and new pledges over RMB 1.029 billion of receivables — tighter bank credit could deepen the credit discount; VBP implementation for bevacizumab/denosumab would hit Baion's consolidated profit and could trigger goodwill/intangible impairments; LY03015 Phase III delay or failure (the 83.3% TEAE rate in Chinese subjects is a key variable for US development); the Nanjing Luye put option (three-year net profit target of RMB 1.086 billion) could create a contingent payment on the order of RMB 1 billion; fair value fluctuations of preferred shares/CBs distort reported profit every quarter; no FX/interest rate hedging.
Catalysts to watch: Q4 2026 LY03015 Phase III protocol finalization and China/US launches; global pipeline partnerships over the next 12 months (management guidance); H1 2027 Ruoxinlin GAD approval and US approvals of Baion's two denosumab products; Nov 2026 NRDL/commercial insurance list results; Mar 2027 annual report as dual validation of "oncology stabilization + short-term debt reduction"; controlling shareholder top-ups or company buybacks (current price is ~17% above Liu Dianbo's last top-up cost).
Report date: 2026-09-03. Price basis: 2026-09-02 closing price of HK$1.845 (completed trading day close). Unless otherwise noted, all financial data in this report are in RMB, sourced from the company's HKEX results announcements; recurring profit and rNPV are estimated in this report. This report does not constitute investment advice.